Anaplastic Oligodendroglioma (AO) Completed Phase 2 Trials for Temozolomide (DB00853)

Also known as: Anaplastic Oligodendroglioma / Anaplastic Oligodendrogliomas / Malignant oligodendroglioma / Oligodendroglioma, anaplastic (morphologic abnormality) / Oligodendroglioma malignant

IndicationStatusPhase
DBCOND0052374 (Anaplastic Oligodendroglioma (AO))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01847235
Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II TrialTreatment
NCT00362570
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed OligoastrocytomaTreatment